Jéssica Obelar

Ms. Jéssica Obelar

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2022 in Atmospheric Pollution Research
Verified
Journal Article
Closed access
AFA.P.S. Ferreira
A.P.S. Ferreira
JOJéssica Obelar
Jéssica Obelar
GGG.D. Gamaro
G.D. Gamaro
AGA. Gioda
A. Gioda
CGC.R. Gioda
C.R. Gioda
ISIzabel Cristina Custódio de Souza
Izabel Cristina Custódio de Souza

31 July 2024 in Chemosphere
Verified
Journal Article
Closed access
LCLílian Corrêa Costa-Beber
Lílian Corrêa Costa-Beber
RMRafael Kazmirczak Moraes
Rafael Kazmirczak Moraes
JOJéssica Obelar
Jéssica Obelar
LMLeo Anderson Meira Martins
Leo Anderson Meira Martins
ATAna Laura Toquetto
Ana Laura Toquetto
FGFátima Theresinha Costa Rodrigues Guma
Fátima Theresinha Costa Rodrigues Guma

27 June 2021 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
CCCaroline Crespo da Costa
Caroline Crespo da Costa
LMLéo Anderson Meira Martins
Léo Anderson Meira Martins
AKAndré Peres Koth
André Peres Koth
JOJéssica Obelar
Jéssica Obelar
FGFatima Theresinha Costa Rodrigues Guma
Fatima Theresinha Costa Rodrigues Guma
ISIzabel Cristina Custódio de Souza
Izabel Cristina Custódio de Souza

9 May 2025 in Environmental Pollution
Verified
Journal Article
Closed access
LCLílian Corrêa Costa-Beber
Lílian Corrêa Costa-Beber
RDRicardo Maia Dantas
Ricardo Maia Dantas
APAriadni Mesquita Peres
Ariadni Mesquita Peres
JOJéssica Obelar
Jéssica Obelar
HFHémelin Resende Farias
Hémelin Resende Farias
FGFatima Theresinha Costa Rodrigues Guma
Fatima Theresinha Costa Rodrigues Guma

24 January 2026 in Neurochemical Research
Verified
Journal Article
Open access
PDF file
NBNatália Baltazar
Natália Baltazar
HFHemelin Farias
Hemelin Farias
TSTainá Schons
Tainá Schons
APAlex Paulo Zeferino Padilha
Alex Paulo Zeferino Padilha
MCMariana Viana Costa
Mariana Viana Costa
JOJade de Oliveira
Jade de Oliveira
Familial hypercholesterolemia (FH), caused by mutations in the low-density lipoprotein receptor (LDLr) gene, has been increasingly associated with neurodegenerative and mood disorders. Studies with LDLR knockout mice (LDLr −/− ) showed that neuroinflammation is a key event in FH-related brain dysfunction. Because mTOR inhibition has been shown to mitigate brain alterations in this model, we hypothesized that metformin, a drug reported to influence cellular energy metabolism, could attenuate FH-associated brain changes. To test this, adult LDLr −/− mice received daily oral doses of metformin (200 mg/Kg) or vehicle for 30 days. During the final week, behavioral assessments were conducted, including the open-field test, novel object recognition and object reallocation tasks, and the tail suspension test (depressive-like behavior). Body weight, total cholesterol and glucose plasma levels were analyzed. Hippocampal astrocyte and microglial density, as well as the expression of genes related to neuroinflammation and synaptic plasticity, were evaluated. Metformin did not alter total cholesterol levels but significantly improved cognitive performance and reduced depressive-like behavior. The treatment also attenuated hippocampal astrogliosis without affecting microglial reactivity. Molecular analysis revealed reduced hippocampal TGF-β gene expression and increased PSD-95 gene expression and protein content in metformin-treated LDLr −/− mice. Although a slight, non-significant reduction in the phosphorylated-to-total mTOR ratio was detected, no clear evidence of AMPK/mTOR pathway modulation was observed. Overall, metformin improved memory function and astrocyte reactivity in LDLr −/− mice independently of cholesterol reduction and without demonstrable involvement of the AMPK/mTOR pathway, suggesting its potential as a therapeutic strategy for FH-associated brain dysfunction.

25 February 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
ASArieli Sousa
Arieli Sousa
AWAugusto Ferreira Weber
Augusto Ferreira Weber
VKVinícius Klain
Vinícius Klain
JSJuliete Nathali Scholl
Juliete Nathali Scholl
JOJéssica Obelar
Jéssica Obelar
FGFatima Theresinha Costa Rodrigues Guma
Fatima Theresinha Costa Rodrigues Guma
Background/Objectives: Dysregulation of purinergic signaling, particularly CD73 overexpression, influences tumor progression, immune evasion, and chemoresistance in hepatocellular carcinoma (HCC). We aimed to characterize the transcriptional landscape of this system, identify prognostic markers, and investigate how the tumor microenvironment modulates pharmacological response to combined sorafenib and doxazosin in 3D spheroid models. Methods: We integrated RNA-seq data from The Cancer Genome Atlas—Liver Hepatocellular Carcinoma (TCGA-LIHC) to identify differentially expressed genes, pathway enrichment, gene co-expression networks, prognostic associations, and machine learning-based biomarker selection. Modulation of key targets was assessed in HepG2 and HepG2/LX-2 spheroids treated with sorafenib and doxazosin using qPCR and flow cytometry. Results: Transcriptomics revealed dysregulation and network fragmentation. Specifically, analysis of the TCGA cohort indicated that high expression of ADA, NT5E, and ADORA1 correlated with poor overall survival. Given the critical role of CD73 in therapy resistance, we evaluated these findings in 3D models. Co-treatment significantly downregulated NT5E and ADORA1 mRNA expression, while ADORA2A was specifically reduced in the co-culture setting. For the ADA, effect-size analysis revealed a large magnitude of inhibition in HepG2 spheroids. Although flow cytometry showed that high CD73 protein expression remained stable across treatments in co-culture, the combination therapy overcame stromal protection, significantly increasing apoptosis (active caspase-3) in both mono- and co-culture spheroids compared with vehicle and monotherapy. Conclusions: We identified a purinergic prognostic signature in HCC and demonstrated that the combination therapy of sorafenib and doxazosin targets the adenosine pathway and specific receptors. We show that the stromal microenvironment sustains CD73 protein expression even under transcriptional inhibition, highlighting the critical role of 3D co-culture models in deciphering therapeutic resistance mechanisms.